New promising data with ColoNode for colon cancer

Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode’s benefits and usefulness in colon cancer.
“The results look promising”, says Lina Olsson, CEO of Hiloprobe AB

Read more

HiloProbe enters strategically important partnership with Biocartis

Umeå based HiloProbe AB has entered a partnership with the major international company Biocartis Group NV. This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode®.
“We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries”, Lina Olsson, CEO of HiloProbe, says.

Read more

HiloProbe Awarded SEK 2 Million by Swedish Innovation Agency

HiloProbe has been granted SEK 2 million from Swedish Innovation Agency Vinnova to validate a product that detects and helps treat people with colorectal cancer.
“This is an important grant for us and means we can validate our product and make it available to the healthcare industry sooner,” says Lina Olsson, CEO of HiloProbe.

Read more

HiloProbe attracts millions in new investment round

Umeå biotech company HiloProbe has attracted millions in new investment capital after successfully developing a diagnostic and prognostic product for colon and rectal cancer.
“Capital is crucial for getting our product to patients and helping them,” says Lina Olsson, HiloProbe’s CEO.

Read more

Cancer-startup Hiloprobe partner up with team of investors and angels

Hiloprobe  AB has signed off on a partnership deal with a group of public and private stakeholders who have come together to back this high-potential startup. Hiloprobe is now complemented with much needed business expertise – as Mattias Pettersson from Northern Light Capital joins the board of directors, The company aims to launch their product for improved colorectal cancer diagnosis by 2020.

Read more

Annual investment event yielded five investor leads per startup

The ninth edition of Biotech Umeå’s annual partnering event was the first ever to fill up before deadline. Around 30 Swedish and European investors met with 13 startups and early cases. Two weeks after the event participants report an impressive turnout – on average they have retained at least five active leads per company.

Read more

High quality line-up great value for both sides at BUID2017

The eight consecutive Biotech Umeå Investment Day attracted almost 30 Swedish and international investors to Blasierummet at Grand Hotel on the 2 of February 2017 in Stockholm. One of the most appreciated aspects of the event was the flexibility to arrange additional ad-hoc partnering meetings and the size and atmosphere at the event.

Read more